Product logins

Find logins to all Clarivate products below.


Obesity – Epidemiology – Epidemiology Dashboard

Clarivate Epidemiology’s coverage of obesity / overweight comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the total obesity / overweight prevalent cases for each country, as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of 20 years for the mature markets and Europe, and 10 years for the other countries we cover.

All forecast data are available on Clarivate’s Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

Clarivate Epidemiology’s obesity / overweight forecast answers the following questions:

  • How will changes in the levels of exposure to known risk or protective factors affect the number of people living with a diagnosis of obesity / overweight and the number of new diagnoses of obesity / overweight?
  • Of all people diagnosed with obesity / overweight, how many in each country across the major mature pharmaceutical markets are drug-treated?
  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of obesity / overweight over the forecast period?

In addition to the total obesity prevalent cases for each forecast year, Clarivate Epidemiology provides at least 10 years of forecast data for the following obesity / overweight subpopulations:

  • Total overweight prevalent cases
  • Total obesity prevalent cases after effective usage of GLP-1RAs
  • Drug and non-drug-eligible overweight prevalent cases
  • Severity
  • Diagnosed and undiagnosed prevalent cases
  • Diagnosed drug and non-drug-treated obesity prevalent cases
  • Diagnosed drug and non-drug-eligible overweight prevalent cases
  • Comorbidity

Note: Coverage may vary by country.

Related Market Assessment Reports

Report
Squamous Cell Carcinoma of the Head and Neck – Landscape & Forecast – Disease Landscape & Forecast (Major Markets)
Squamous cell carcinoma of the head and neck (SCCHN) is the seventh most commonly diagnosed cancer. It encompasses a spectrum of heterogeneous tumors originating at multiple sites in the head and…
Report
Acute Coronary Syndrome – Landscape & Forecast – Disease Landscape & Forecast (G7)
Acute coronary syndrome (ACS) is a leading cause of morbidity and mortality in developed countries. Despite aggressive management of atherothrombotic risk factors through LDL-C lowering, blood-…
Report
Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease – Current Treatment – Treatment Algorithms: Claims Data Analysis – Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (US)
Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAAD) is a rare autoimmune inflammatory CNS disorder defined by IgG antibodies targeting the myelin oligodendrocyte glycoprotein…
Report
Obesity – Current Treatment – Treatment Algorithms: Claims Data Analysis – Obesity (US)
GLP-1 RA products have set new standards for weight-loss drugs and are driving the rapid growth of the obesity market. Novo Nordisk’s semaglutide (Wegovy) and Eli Lilly’s tirzepatide (Zepbound…
Report
Non-Small-Cell Lung Cancer – Landscape & Forecast – Disease Landscape & Forecast (G7)
The multibillion-dollar NSCLC therapy market is highly dynamic, with more than 40 targeted drugs approved, but still a high unmet need. Immune checkpoint inhibitors such as Keytruda (Merck & Co.)…